About: IgY - turning the page toward passive immunization in COVID-19 infection (Review)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: IgY - turning the page toward passive immunization in COVID-19 infection (Review) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	IgY - turning the page toward passive immunization in COVID-19 infection (Review)
Creator	Spandidos, Demetrios Chiurciu, Viorica Constantin, Carolina Neagu, Monica Supeanu, Teodora
Source	Medline; PMC
abstract	The world is facing one of the major outbreaks of viral infection of the modern history, however, as vaccine development workflow is still tedious and can not control the infection spreading, researchers are turning to passive immunization as a good and quick alternative to treat and contain the spreading. Within passive immunization domain, raising specific immunoglobulin (Ig)Y against acute respiratory tract infection has been developing for more than 20 years. Far from being an obsolete chapter we will revise the IgY-technology as a new frontier for research and clinic. A wide range of IgY applications has been effectively confirmed in both human and animal health. The molecular particularities of IgY give them functional advantages recommending them as good candidates in this endeavor. Obtaining specific IgY is sustained by reliable and nature friendly methodology as an alternative for mammalian antibodies. The aria of application is continuously enlarging from bacterial and viral infections to tumor biology. Specific anti-viral IgY were previously tested in several designs, thus its worth pointing out that in the actual COVID-19 pandemic context, respiratory infections need an enlarged arsenal of therapeutic approaches and clearly the roles of IgY should be exploited in depth.
has issue date	2020-04-30(xsd:dateTime)
bibo:doi	10.3892/etm.2020.8704
bibo:pmid	32536989
has license	cc-by-nc-nd
sha1sum (hex)	b22d582f281ab8d0ef91b0e812c3b243db948725
schema:url	https://doi.org/10.3892/etm.2020.8704
resource representing a document's title	IgY - turning the page toward passive immunization in COVID-19 infection (Review)
has PubMed Central identifier	PMC7282020
has PubMed identifier	32536989
schema:publication	Exp Ther Med
resource representing a document's body	covid:b22d582f281ab8d0ef91b0e812c3b243db948725#body_text
is schema:about of	named entity 'human' named entity 'The' named entity 'IgY' named entity 'APPROACHES' named entity 'CONTEXT' named entity 'THERAPEUTIC' named entity 'IMMUNOGLOBULIN' named entity 'VACCINE DEVELOPMENT' named entity 'MAMMALIAN' named entity 'DEPTH' named entity 'FUNCTIONAL' named entity 'ARIA' named entity 'TUMOR BIOLOGY' named entity 'CONTROL' named entity 'POINTING' named entity 'ANIMAL HEALTH' named entity 'respiratory infections' named entity 'exploited' named entity 'good' named entity 'actual' named entity 'treat' named entity 'enlarged' named entity 'The' named entity 'anti-viral' named entity 'respiratory infections' named entity 'IgY' named entity 'IgY' named entity 'therapeutic approaches' named entity 'vaccine' named entity 'passive immunization' named entity 'infection' named entity 'infection' named entity 'Respiratory tract infections' named entity 'inflammation' named entity 'SARS coronavirus' named entity 'rapid response' named entity 'Passive immunization' named entity 'half-life' named entity 'IgY' named entity 'RSV' named entity 'mAbs' named entity 'murine' named entity 'COVID-19 pandemic' named entity 'IgY' named entity 'monoclonality' named entity 'Chromatographic methods' named entity 'antibodies' named entity 'neutrophils' named entity 'PSA level' named entity 'chicken' named entity 'antibiotics' named entity 'viral particle' named entity 'influenza virus' named entity 'passive immunity' named entity 'antigen' named entity 'IgY' named entity 'amphibians' named entity 'systemic administration' named entity 'selective pressure' named entity 'primary immunodeficiency' named entity 'passive immunization' named entity 'rotavirus' named entity 'infection' named entity 'Passive immunization' named entity 'clinical trial phase' named entity 'viral proteins' named entity 'egg yolk' named entity 'sandwich ELISA' named entity 'RTI' named entity 'antibodies' named entity 'infection' named entity 'Fc receptors' named entity 'parasitology' named entity 'IgY' named entity 'short-term' named entity 'type III secretion' named entity 'influenza virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software